Illumina Releases 2025 Corporate Responsibility Report Highlighting Genomic Access and Sustainability
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 6 days ago
0mins
Source: Newsfilter
- Genomic Access Expansion: In 2025, Illumina partnered with governments and health systems to promote population-scale genomics, aiming to enhance global access to genomic medicine, which is expected to significantly improve patient health outcomes.
- Sustainability Achievements: Since 2019, Illumina has reduced product packaging by 87%, surpassing its 2030 target, while achieving a 74% reduction in greenhouse gas emissions and utilizing 100% renewable electricity for the fourth consecutive year, showcasing its leadership in sustainability.
- Community Engagement: Illumina has maintained a zero pay gap for seven consecutive years and achieved over 116,000 volunteer hours in 2025, demonstrating the company's commitment to its employees and community while promoting science education.
- Technological Innovations: In 2025, Illumina launched several new technologies, including the Illumina 5-base solution and PromoterAI, further enhancing its oncology product portfolio and driving the widespread application of genomic technologies.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ILMN?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ILMN
Wall Street analysts forecast ILMN stock price to fall
13 Analyst Rating
4 Buy
6 Hold
3 Sell
Hold
Current: 144.410
Low
40.50
Averages
133.54
High
170.00
Current: 144.410
Low
40.50
Averages
133.54
High
170.00
About ILMN
Illumina, Inc. specializes in DNA sequencing and array-based technologies, serving customers in research, clinical and applied markets. The Company's products are used for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. Its customers include genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. Its comprehensive line of products addresses the scale of experimentation and breadth of functional analysis to advance disease research, drug development, and the development of molecular tests. It also specializes in data-driven proteomics technology. Its products include instruments, kits and reagents, selection tools, and software and analysis. Its services include sequencing services, microarray services, proactive instrument monitoring, and instrument services and training.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Illumina Elects David P. King to Board of Directors
- New Board Member: Illumina has elected David P. King to its Board of Directors, a move aimed at accelerating the company's clinical strategy to integrate genomics more broadly into standard care, which is expected to enhance its competitiveness in the healthcare sector.
- Extensive Leadership Experience: King previously served as Executive Chairman and CEO of Labcorp, where he led the company to triple its size through organic growth and strategic acquisitions, showcasing his deep expertise in healthcare and life sciences.
- Industry Influence: King's addition will strengthen Illumina's long-term impact for patients, customers, and shareholders, particularly through his expertise in healthcare delivery and board governance, providing strategic advantages for the company.
- Board Restructuring: King's election follows the retirement of Frances Arnold, Robert S. Epstein, and Gary S. Guthart, marking a continued optimization and renewal of Illumina's leadership team.
See More
Illumina Elects David P. King to Board of Directors
- New Board Member: Illumina has confirmed the election of David P. King to its Board of Directors, marking a significant step as the company accelerates its clinical strategy to integrate genomics into standard care.
- Rich Industry Experience: King, former CEO of Labcorp, led the company to triple its size through organic growth and strategic acquisitions, bringing deep regulatory knowledge and industry credibility that is expected to enhance Illumina's long-term impact.
- Leadership and Governance: Under King's leadership, Labcorp entered the Fortune 500 and was recognized as one of the World's Most Admired Companies, and his extensive experience in healthcare and life sciences will strengthen Illumina's board governance capabilities.
- Strategic Advisory Role: King also serves on the boards of several healthcare companies and provides strategic advisory services through KingMan LLC, and his rich background will provide crucial support for Illumina's future development.
See More
Illumina Releases 2025 Corporate Responsibility Report
- Genomics Accessibility Progress: In 2025, Illumina achieved sequencing speeds exceeding 10 human genomes per minute, indicating significant advancements in personalized medicine that are expected to improve health outcomes for patients globally.
- Sustainability Achievements: Since 2019, Illumina has reduced product packaging by 87%, surpassing its 2030 target, while achieving a 74% reduction in greenhouse gas emissions and utilizing 100% renewable electricity for the fourth consecutive year, showcasing its leadership in environmental stewardship.
- Community Engagement and Volunteering: Illumina has maintained a zero pay gap for seven consecutive years and achieved over 116,000 volunteer hours in 2025, reflecting the company's ongoing commitment to its employees and community, while promoting science education outreach.
- Technological Innovation and Collaboration: In 2025, Illumina launched several new technologies, including the Illumina 5-base solution and PromoterAI, further strengthening its partnerships with global collaborators to enhance the application of genomic technologies in clinical and public health settings.
See More
Illumina Releases 2025 Corporate Responsibility Report Highlighting Genomic Access and Sustainability
- Genomic Access Expansion: In 2025, Illumina partnered with governments and health systems to promote population-scale genomics, aiming to enhance global access to genomic medicine, which is expected to significantly improve patient health outcomes.
- Sustainability Achievements: Since 2019, Illumina has reduced product packaging by 87%, surpassing its 2030 target, while achieving a 74% reduction in greenhouse gas emissions and utilizing 100% renewable electricity for the fourth consecutive year, showcasing its leadership in sustainability.
- Community Engagement: Illumina has maintained a zero pay gap for seven consecutive years and achieved over 116,000 volunteer hours in 2025, demonstrating the company's commitment to its employees and community while promoting science education.
- Technological Innovations: In 2025, Illumina launched several new technologies, including the Illumina 5-base solution and PromoterAI, further enhancing its oncology product portfolio and driving the widespread application of genomic technologies.
See More
Grail Stock Volatility and Future Outlook
- Stock Volatility: Grail's stock was spun off from Illumina in June 2024, starting at $13.95 per share and peaking at $116.06 on January 22, 2026, but now trades around $60, indicating market concerns about its future prospects.
- Trial Result Failure: Grail's Galleri blood test missed its primary endpoint in the largest NHS trial, prompting Canaccord Genuity to lower its price target from $105 to $80, reflecting investor disappointment in its potential.
- Revenue Growth and Losses: Despite Grail's revenue increasing from $93 million in 2023 to $147 million in 2025, with net losses narrowing from $1.47 billion to $408 million, analysts expect revenue to rise 25% to $224 million in 2027, with losses widening to $485 million, indicating ongoing profitability challenges.
- Uncertain Market Outlook: While Galleri has significant sales potential if FDA approval and insurance coverage are achieved, the NHS trial results suggest these catalysts may not materialize soon, requiring investors to approach this speculative opportunity with caution.
See More
Latest Wall Street Rating Updates
- Nvidia Price Target Raised: UBS raised Nvidia's price target from $245 to $275, anticipating first-quarter revenue around $81 billion, suggesting a $3 billion beat against market expectations, highlighting the company's robust growth potential in the AI sector.
- Amazon Alexa Shopping Advantage: Bank of America reiterated its buy rating on Amazon, stating that the new Alexa for Shopping will replace Rufus, leveraging personalized recommendations to enhance user experience and further solidify Amazon's leadership in the e-commerce market.
- Apple Stock Price Target Increase: Evercore raised Apple's price target from $330 to $365, projecting that even with modest iPhone unit growth, the company can achieve low to mid-teens EPS and free cash flow growth due to durable services growth and ASP tailwinds from premium models.
- Starbucks Price Target Upgraded: TD Cowen raised Starbucks' price target from $106 to $120, citing multiple tangible drivers for positive sales revisions in a strong market backdrop, and forecasting margin recovery as labor investments are prioritized.
See More
Illumina Elects David P. King to Board of Directors
- New Board Member: Illumina has elected David P. King to its Board of Directors, a move aimed at accelerating the company's clinical strategy to integrate genomics more broadly into standard care, which is expected to enhance its competitiveness in the healthcare sector.
- Extensive Leadership Experience: King previously served as Executive Chairman and CEO of Labcorp, where he led the company to triple its size through organic growth and strategic acquisitions, showcasing his deep expertise in healthcare and life sciences.
- Industry Influence: King's addition will strengthen Illumina's long-term impact for patients, customers, and shareholders, particularly through his expertise in healthcare delivery and board governance, providing strategic advantages for the company.
- Board Restructuring: King's election follows the retirement of Frances Arnold, Robert S. Epstein, and Gary S. Guthart, marking a continued optimization and renewal of Illumina's leadership team.
See More
Illumina Elects David P. King to Board of Directors
- New Board Member: Illumina has confirmed the election of David P. King to its Board of Directors, marking a significant step as the company accelerates its clinical strategy to integrate genomics into standard care.
- Rich Industry Experience: King, former CEO of Labcorp, led the company to triple its size through organic growth and strategic acquisitions, bringing deep regulatory knowledge and industry credibility that is expected to enhance Illumina's long-term impact.
- Leadership and Governance: Under King's leadership, Labcorp entered the Fortune 500 and was recognized as one of the World's Most Admired Companies, and his extensive experience in healthcare and life sciences will strengthen Illumina's board governance capabilities.
- Strategic Advisory Role: King also serves on the boards of several healthcare companies and provides strategic advisory services through KingMan LLC, and his rich background will provide crucial support for Illumina's future development.
See More
Illumina Releases 2025 Corporate Responsibility Report
- Genomics Accessibility Progress: In 2025, Illumina achieved sequencing speeds exceeding 10 human genomes per minute, indicating significant advancements in personalized medicine that are expected to improve health outcomes for patients globally.
- Sustainability Achievements: Since 2019, Illumina has reduced product packaging by 87%, surpassing its 2030 target, while achieving a 74% reduction in greenhouse gas emissions and utilizing 100% renewable electricity for the fourth consecutive year, showcasing its leadership in environmental stewardship.
- Community Engagement and Volunteering: Illumina has maintained a zero pay gap for seven consecutive years and achieved over 116,000 volunteer hours in 2025, reflecting the company's ongoing commitment to its employees and community, while promoting science education outreach.
- Technological Innovation and Collaboration: In 2025, Illumina launched several new technologies, including the Illumina 5-base solution and PromoterAI, further strengthening its partnerships with global collaborators to enhance the application of genomic technologies in clinical and public health settings.
See More
Illumina Releases 2025 Corporate Responsibility Report Highlighting Genomic Access and Sustainability
- Genomic Access Expansion: In 2025, Illumina partnered with governments and health systems to promote population-scale genomics, aiming to enhance global access to genomic medicine, which is expected to significantly improve patient health outcomes.
- Sustainability Achievements: Since 2019, Illumina has reduced product packaging by 87%, surpassing its 2030 target, while achieving a 74% reduction in greenhouse gas emissions and utilizing 100% renewable electricity for the fourth consecutive year, showcasing its leadership in sustainability.
- Community Engagement: Illumina has maintained a zero pay gap for seven consecutive years and achieved over 116,000 volunteer hours in 2025, demonstrating the company's commitment to its employees and community while promoting science education.
- Technological Innovations: In 2025, Illumina launched several new technologies, including the Illumina 5-base solution and PromoterAI, further enhancing its oncology product portfolio and driving the widespread application of genomic technologies.
See More
Grail Stock Volatility and Future Outlook
- Stock Volatility: Grail's stock was spun off from Illumina in June 2024, starting at $13.95 per share and peaking at $116.06 on January 22, 2026, but now trades around $60, indicating market concerns about its future prospects.
- Trial Result Failure: Grail's Galleri blood test missed its primary endpoint in the largest NHS trial, prompting Canaccord Genuity to lower its price target from $105 to $80, reflecting investor disappointment in its potential.
- Revenue Growth and Losses: Despite Grail's revenue increasing from $93 million in 2023 to $147 million in 2025, with net losses narrowing from $1.47 billion to $408 million, analysts expect revenue to rise 25% to $224 million in 2027, with losses widening to $485 million, indicating ongoing profitability challenges.
- Uncertain Market Outlook: While Galleri has significant sales potential if FDA approval and insurance coverage are achieved, the NHS trial results suggest these catalysts may not materialize soon, requiring investors to approach this speculative opportunity with caution.
See More
Latest Wall Street Rating Updates
- Nvidia Price Target Raised: UBS raised Nvidia's price target from $245 to $275, anticipating first-quarter revenue around $81 billion, suggesting a $3 billion beat against market expectations, highlighting the company's robust growth potential in the AI sector.
- Amazon Alexa Shopping Advantage: Bank of America reiterated its buy rating on Amazon, stating that the new Alexa for Shopping will replace Rufus, leveraging personalized recommendations to enhance user experience and further solidify Amazon's leadership in the e-commerce market.
- Apple Stock Price Target Increase: Evercore raised Apple's price target from $330 to $365, projecting that even with modest iPhone unit growth, the company can achieve low to mid-teens EPS and free cash flow growth due to durable services growth and ASP tailwinds from premium models.
- Starbucks Price Target Upgraded: TD Cowen raised Starbucks' price target from $106 to $120, citing multiple tangible drivers for positive sales revisions in a strong market backdrop, and forecasting margin recovery as labor investments are prioritized.
See More
